A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Monotherapy Study to Determine the Efficacy and Safety of 2 Dose Levels of Albiglutide in Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase III
Latest Information Update: 14 Jun 2016
At a glance
- Drugs Albiglutide (Primary) ; Liraglutide
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 17 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 13 Jan 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Jun 2014 as reported by ClinicalTrials.gov record.